These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38425446)

  • 21. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
    Sandborn WJ; Lawendy N; Danese S; Su C; Loftus EV; Hart A; Dotan I; Damião AOMC; Judd DT; Guo X; Modesto I; Wang W; Panés J
    Aliment Pharmacol Ther; 2022 Feb; 55(4):464-478. PubMed ID: 34854095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
    Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
    Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.
    Rubin DT; Reinisch W; Greuter T; Kotze PG; Pinheiro M; Mundayat R; Maller E; Fellmann M; Lawendy N; Modesto I; Vavricka SR; Lichtenstein GR
    Therap Adv Gastroenterol; 2021; 14():17562848211005708. PubMed ID: 34035832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
    Winthrop KL; Yndestad A; Henrohn D; Danese S; Marsal S; Galindo M; Woolcott JC; Jo H; Kwok K; Shapiro AB; Jones TV; Diehl A; Su C; Panés J; Cohen SB
    Rheumatol Ther; 2023 Apr; 10(2):357-373. PubMed ID: 36526796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
    Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
    Schreiber S; Rubin DT; Ng SC; Peyrin-Biroulet L; Danese S; Modesto I; Guo X; Su C; Kwok KK; Jo H; Chen Y; Yndestad A; Reinisch W; Dubinsky MC
    J Crohns Colitis; 2023 Nov; 17(11):1761-1770. PubMed ID: 37402275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
    Kristensen LE; Danese S; Yndestad A; Wang C; Nagy E; Modesto I; Rivas J; Benda B
    Ann Rheum Dis; 2023 Jul; 82(7):901-910. PubMed ID: 36931693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.
    Vavricka SR; Greuter T; Cohen BL; Reinisch W; Steinwurz F; Fellmann M; Guo X; Lawendy N; Paulissen J; Peyrin-Biroulet L
    Therap Adv Gastroenterol; 2022; 15():17562848221090834. PubMed ID: 35574426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
    Dubinsky MC; Magro F; Steinwurz F; Hudesman DP; Kinnucan JA; Ungaro RC; Neurath MF; Kulisek N; Paulissen J; Su C; Ponce de Leon D; Regueiro M
    Inflamm Bowel Dis; 2023 Jan; 29(1):51-61. PubMed ID: 35380664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
    Lichtenstein GR; Cohen BL; Salese L; Modesto I; Wang W; Chan G; Ahmed HM; Su C; Peyrin-Biroulet L
    Dig Dis Sci; 2023 Jun; 68(6):2624-2634. PubMed ID: 36739367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified Mayo score
    Sandborn WJ; Sands BE; Vermeire S; Leung Y; Guo X; Modesto I; Su C; Wang W; Panés J
    Therap Adv Gastroenterol; 2022; 15():17562848221136331. PubMed ID: 36506749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
    Panés J; Vermeire S; Dubinsky MC; Loftus EV; Lawendy N; Wang W; Salese L; Su C; Modesto I; Guo X; Colombel JF
    J Crohns Colitis; 2021 Nov; 15(11):1852-1863. PubMed ID: 33884415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
    Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
    Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
    Lee SD; Allegretti JR; Steinwurz F; Connelly SB; Lawendy N; Paulissen J; Gecse KB
    BMC Gastroenterol; 2023 Feb; 23(1):34. PubMed ID: 36755231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
    Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
    Feagan BG; Khanna R; Sandborn WJ; Vermeire S; Reinisch W; Su C; Salese L; Fan H; Paulissen J; Woodworth DA; Niezychowski W; Sands BE
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1442-1453. PubMed ID: 34614208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.